Niagen Bioscience, Inc. (NAGE)

NASDAQ: NAGE · Real-Time Price · USD
9.63
0.00 (0.00%)
At close: Aug 20, 2025, 4:00 PM
9.61
-0.02 (-0.21%)
Pre-market: Aug 21, 2025, 4:00 AM EDT
Market Cap769.63M
Revenue (ttm)116.30M
Net Income (ttm)17.73M
Shares Out 79.92M
EPS (ttm)0.22
PE Ratio44.74
Forward PE64.20
Dividendn/a
Ex-Dividend Daten/a
Volume536,554
Open9.52
Previous Close9.63
Day's Range9.37 - 9.70
52-Week Range3.10 - 14.69
Beta2.12
AnalystsStrong Buy
Price Target17.00 (+76.53%)
Earnings DateAug 6, 2025

About NAGE

Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+) test kits to healthcare practitioners; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and ph... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1999
Employees 104
Stock Exchange NASDAQ
Ticker Symbol NAGE
Full Company Profile

Financial Performance

Financial Statements

Analyst Summary

According to 3 analysts, the average rating for NAGE stock is "Strong Buy." The 12-month stock price target is $17.0, which is an increase of 76.53% from the latest price.

Price Target
$17.0
(76.53% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Niagen Bioscience, Inc. Reports Second Quarter 2025 Financial Results and Increases Full Year Outlook

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ:NAGE) today announced financial results for the second quarter of 2025. Second Quarter 2025 Financial Highlights Compar...

14 days ago - Business Wire

Niagen Bioscience to Present at Canaccord Genuity's 45th Annual Growth Conference

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the...

16 days ago - Business Wire

Niagen Bioscience to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the...

4 weeks ago - Business Wire

Niagen Bioscience Announces the Debut of Tru Niagen® and Niagen IV at Equinox Hotel New York

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the...

5 weeks ago - Business Wire

Niagen Bioscience Secures Exclusive License to Develop and Commercialize its NAD+ Precursor, Patented Nicotinamide Riboside (Niagen®), as a Potential Parkinson's Disease Therapy in Agreement with Haukeland University Hospital in Bergen, Norway

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the...

6 weeks ago - Business Wire

Niagen Biosciences: Anti-Aging Market Leader And Prime Beneficiary Of Long-Term Demographic Trends

NAGE is a leader in the growing NAD+ supplement market, benefiting from rising health and longevity trends and strong brand awareness with its flagship Tru Niagen product. Analyst estimates for 2025 r...

2 months ago - Seeking Alpha

Niagen Bioscience to Participate at the Roth 15th Annual London Conference

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the...

2 months ago - Business Wire

Niagen Bioscience to Participate in the BIO 2025 International Convention

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the...

2 months ago - Business Wire

Niagen Bioscience: High Conviction, High Expectations

Niagen Bioscience's stock price is breaking out with strong fundamentals, proprietary IP, and a leadership position in the NAD+ longevity market. Revenue and margins are rising, driven by Tru Niagen e...

2 months ago - Seeking Alpha

Niagen Bioscience Announces First-Ever Peer-Reviewed Study Highlighting the Potential of Nicotinamide Riboside (NR) for Werner Syndrome, a Rare Genetic Disorder

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the...

2 months ago - Business Wire

Niagen Bioscience to Present at Oppenheimer's 25th Annual Consumer Growth and E-Commerce Conference

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #InvestorRelations--Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a fo...

2 months ago - Business Wire

Niagen Bioscience, Inc. (NAGE) Q1 202 Earnings Call Transcript

Niagen Bioscience, Inc. Q1 2025 - Earnings Conference Call May 7, 2025 4:30 PM ET Company Participants Wesley Yu - VP of Finance Rob Fried - CEO Ozan Pamir - CFO Andrew Shao - SVP, Scientific & Regula...

3 months ago - Seeking Alpha

Niagen Bioscience, Inc. Reports First Quarter 2025 Financial Results and Increases Outlook

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Bioscience--Niagen Bioscience, Inc. (NASDAQ:NAGE) today announced financial results for the first quarter of 2025. First Quarter 2025 Financial and Recent Opera...

3 months ago - Business Wire

Niagen Bioscience Announces Pharmaceutical-Grade Niagen® IV Is Now Available in Almost 600 Clinics Nationwide

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Bioscience--Niagen Bioscience, Inc. (Nasdaq: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on ...

3 months ago - Business Wire

Niagen Bioscience Welcomes Dr. Pinchas Cohen to Scientific Advisory Board

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Bioscience--Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on ...

4 months ago - Business Wire

Niagen Bioscience to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Bioscience--Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on ...

4 months ago - Business Wire

Niagen Bioscience Confirms Its Operations Remain Unaffected by New Tariffs

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Bioscience--Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on ...

4 months ago - Business Wire

Niagen Bioscience Confirms Its Operations Remain Resilient Amid New Tariff Developments

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Bioscience--Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on ...

4 months ago - Business Wire

Niagen Bioscience Secures U.S. Patent for the Composition of Matter for Nicotinamide Riboside (NR) Salt Forms

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #IP--Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the scie...

5 months ago - Business Wire

ChromaDex Evolves Into Niagen Bioscience, Marking a New Era of Uncovering the Potential of NAD+ With Precision Science

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Bioscience--Niagen Bioscience, Inc. (Nasdaq: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on ...

5 months ago - Business Wire

ChromaDex Corp. Announces Name Change to Niagen Bioscience, Inc. and New Ticker Symbol "NAGE" Effective March 19, 2025

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #InvestorRelations--ChromaDex Corp. (NASDAQ:CDXC), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging,...

5 months ago - Business Wire

ChromaDex to Present at the 37th Annual Roth Conference

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ: CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) with a focus on the science of healthy aging, today ...

5 months ago - Business Wire

ChromaDex Capitalizes On Longevity Boom But Valuation Remains High

ChromaDex Corporation shows strong revenue growth and profitability, driven by its NAD+ precursors and flagship product Niagen, despite high valuation and execution risks. Record-breaking financial pe...

5 months ago - Seeking Alpha

ChromaDex Corporation (CDXC) Q4 2024 Earnings Call Transcript

ChromaDex Corporation (NASDAQ:CDXC) Q4 2024 Earnings Conference Call March 4, 2025 4:30 PM ET Company Participants Ben Shamsian - Vice President, Lytham Partners, Investor Relations Rob Fried - Chief...

6 months ago - Seeking Alpha

ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2024 Results

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ:CDXC) today announced fourth quarter and fiscal year 2024 financial results. Fourth Quarter 2024 Total net sales of $29.1 mil...

6 months ago - Business Wire